1. Home
  2. KRG vs CRSP Comparison

KRG vs CRSP Comparison

Compare KRG & CRSP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Kite Realty Group Trust

KRG

Kite Realty Group Trust

N/A

Current Price

$25.71

Market Cap

4.8B

Sector

Real Estate

ML Signal

N/A

Logo CRISPR Therapeutics AG

CRSP

CRISPR Therapeutics AG

N/A

Current Price

$50.12

Market Cap

4.8B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
KRG
CRSP
Founded
1971
2013
Country
United States
Switzerland
Employees
N/A
N/A
Industry
Real Estate Investment Trusts
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
4.8B
4.8B
IPO Year
2004
2016

Fundamental Metrics

Financial Performance
Metric
KRG
CRSP
Price
$25.71
$50.12
Analyst Decision
Hold
Buy
Analyst Count
12
23
Target Price
$28.60
★ $85.63
AVG Volume (30 Days)
★ 1.9M
1.5M
Earning Date
10-30-2026
11-13-2026
Dividend Yield
★ 4.63%
N/A
EPS Growth
★ 6750.00
N/A
EPS
★ 0.78
N/A
Revenue
★ $844,365,000.00
$289,590,000.00
Revenue This Year
N/A
$1,052.09
Revenue Next Year
$2.41
$280.75
P/E Ratio
$29.68
★ N/A
Revenue Growth
0.30
★ 9169.85
52 Week Low
$21.70
$44.12
52 Week High
$29.92
$63.45

Technical Indicators

Market Signals
Indicator
KRG
CRSP
Relative Strength Index (RSI) 62.58 45.59
Support Level $23.72 $50.02
Resistance Level $26.52 $60.68
Average True Range (ATR) 0.43 2.32
MACD 0.17 0.27
Stochastic Oscillator 96.99 37.71

Price Performance

Historical Comparison
KRG
CRSP

About KRG Kite Realty Group Trust

Kite Realty Group Trust specializing in high-quality, open-air shopping centers and mixed-use assets. Concentrated in the Sun Belt and strategic gateway markets, the company focuses on grocery-anchored, necessity-based retail. The company generates the majority of its revenue from contractual rents and reimbursement payments received from tenants.

About CRSP CRISPR Therapeutics AG

Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.

Share on Social Networks: